ArticleAdvanced therapeutics2020
Emerging technologies for local cancer treatment.
Article in Advanced therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Nanomedicine beyond carriers - devices, cells & living therapeutics.Biomedical microdevices · 2026Review
- Article
- Targeted immunomodulation for chronic diseases through advanced delivery platforms.Expert opinion on drug delivery · 2026Review
- Silk protein plastics for sustained and controlled drug release.International journal of pharmaceutics · 2026Article
- Tailoring the Release of Paclitaxel from Electrospun Nonwovens.International journal of molecular sciences · 2025Article
- Dual-Modality Ultrasound Imaging of SPIONs Distribution via Combined Magnetomotive and Passive Cavitation Imaging.Sensors (Basel, Switzerland) · 2025Article
- Neural stem cell-delivered oncolytic virus via intracerebroventricular administration enhances glioblastoma therapy and immune modulation.Journal for immunotherapy of cancer · 2025Article
- Small molecular chelator for comprehensive regulation of tumor lactate levels in synergy with photodynamic therapy for cancer treatment.Asian journal of pharmaceutical sciences · 2025Article
- Ionizable lipid nanoparticles with functionalized PEG-lipids increase retention in the tumor microenvironment.Molecular therapy. Methods & clinical development · 2025Article
- Glucose-Fueled Gated Nanomotors: EnhancingACS nano · 2025Article
- Efficient chemo-immunotherapy leveraging minimalist electrostatic complex nanoparticle as "in situ" vaccine integrated tumor ICD and immunoagonist.Journal of advanced research · 2025Article
- Acoustically Driven Hybrid Nanocrystals for In Vivo Pancreatic Cancer Treatment.ACS applied materials & interfaces · 2025Article
- Challenges in the preclinical design and assessment of CAR-T cells.Frontiers in immunology · 2025Review
- Nanofluidic delivery implant sustains localization and maximizes efficacy of intratumoral immunotherapy.Nano today · 2024Article
- Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockade.Journal for immunotherapy of cancer · 2024Article
- Intratumoral Injection of Large Surface Area Microparticle Taxanes in Carcinomas Increases Immune Effector Cell Concentrations, Checkpoint Expression, and Synergy with Checkpoint Inhibitors: A Review of Preclinical and Clinical Studies.Oncology and therapy · 2024Review
- Article
- In-vivo studies of targeted and localized cancer drug release from microporous poly-di-methyl-siloxane (PDMS) devices for the treatment of triple negative breast cancer.Scientific reports · 2024Article
- Localized radiotherapy of solid tumors using radiopharmaceutical loaded implantable system: insights from a mathematical model.Frontiers in oncology · 2024Article
- Intratumoral nanofluidic system enhanced tumor biodistribution of PD-L1 antibody in triple-negative breast cancer.Bioengineering & translational medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The fundamental limitations of systemic therapeutic administration have prompted the development of local drug delivery platforms as a solution to increase effectiveness and reduce side effects. By confining therapeutics to the site of disease, local delivery technologies can enhance therapeutic index. This review highlights recent advances and opportunities in local drug delivery strategies for cancer treatment in addition to challenges that need to be addressed to facilitate clinical translation. The benefits of local cancer treatment combined with technological advancements and increased understanding of the tumor microenvironment, present a prime breakthrough opportunity for safer and more effective therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.